|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:average_temperature
|
-70 degrees Celsius
|
|
gptkbp:booster_recommendation
|
yes
|
|
gptkbp:clinical_trial
|
gptkb:Argentina
gptkb:Brazil
gptkb:Germany
gptkb:Turkey
gptkb:United_States
Phase 2
over 43,000
|
|
gptkbp:developed_by
|
gptkb:Pfizer
gptkb:Bio_NTech
|
|
gptkbp:dosage_form
|
two doses
|
|
gptkbp:effective_date
|
December 2020
|
|
gptkbp:first_dose
|
initial immune response
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BNT162b4
|
|
gptkbp:is_effective_against
|
95% effective
|
|
gptkbp:is_vulnerable_to
|
global
community outreach programs
grants and donations
multiple countries
safety monitoring
ongoing studies
logistical issues
lipid nanoparticle
preventive vaccine
complex supply chain
reduced severe disease
high acceptance rate
reduced transmission
equitable access initiatives
multi-phase trials
reduced hospitalization
significant impact on pandemic control
stringent review process
|
|
gptkbp:manufacturer
|
gptkb:Pfizer-Bio_NTech
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:Comirnaty
|
|
gptkbp:mechanism_of_action
|
induces immune response
|
|
gptkbp:regulatory_compliance
|
Emergency Use Authorization
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:second_dose
|
boost immune response
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
chills
|
|
gptkbp:supply_chain
|
cold chain logistics
|
|
gptkbp:targets
|
gptkb:COVID-19
Spike protein
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:vaccine_adaptation
|
variant-specific formulations
|
|
gptkbp:vaccine_cold_chain
|
temperature-sensitive transport
|
|
gptkbp:vaccine_communication
|
public health campaigns
|
|
gptkbp:vaccine_efficacy_duration
|
at least 6 months
|
|
gptkbp:vaccine_efficacy_studies
|
peer-reviewed studies
|
|
gptkbp:vaccine_ethical_considerations
|
equity in access
|
|
gptkbp:vaccine_funding
|
government and private funding
|
|
gptkbp:vaccine_future_research
|
improving formulations
|
|
gptkbp:vaccine_global_distribution
|
international cooperation
|
|
gptkbp:vaccine_long_term_studies
|
ongoing long-term studies
|
|
gptkbp:vaccine_partnership
|
gptkb:Partnerships
|
|
gptkbp:vaccine_safety_profile
|
generally well-tolerated
|
|
gptkbp:vaccine_storage_requirements
|
special storage conditions
|
|
gptkbp:wholisting
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Bio_NTech
|
|
gptkbp:bfsLayer
|
5
|